# 바이오스페이스 일일 뉴스 리포트 - 2025년 12월 16일


## 주요 헤드라인

1. **Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/immunome-heads-to-the-fda-with-desmoid-tumor-drug-after-phase-iii-sweep>

2. **Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/immunome-heads-to-the-fda-with-desmoid-tumor-drug-after-phase-iii-sweep>

3. **Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/sanofi-taps-dren-again-in-up-to-1-7b-autoimmune-partnership>

4. **Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/sanofi-taps-dren-again-in-up-to-1-7b-autoimmune-partnership>

5. **Argenyx’s Vyvgart Flops Phase III Thyroid Eye Disease Test, Raising Risk for Ongoing Trials (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/argenyxs-vyvgart-flops-phase-iii-thyroid-eye-disease-test-raising-risk-for-ongoing-trials>

6. **Argenyx’s Vyvgart Flops Phase III Thyroid Eye Disease Test, Raising Risk for Ongoing Trials (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/argenyxs-vyvgart-flops-phase-iii-thyroid-eye-disease-test-raising-risk-for-ongoing-trials>

7. **Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/sanofis-ms-drug-fails-phase-iii-trial-while-fda-again-delays-approval-application>


---
*2025년 12월 16일 바이오스페이스 뉴스 피드에서 생성된 리포트*